Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

IGF-1 lr3

Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor-1 Long Arg3

Quick Stats
Studies 41
Trials 0
Score 2
2014 pubmed 8 citations

Epidermal growth factor receptor is required for estradiol-stimulated bovine satellite cell proliferation.

Reiter. B C BC; Kamanga-Sollo. E E; Pampusch. M S MS; White. M E ME; Dayton. W R WR

Key Findings

  • Blocking EGFR with a drug stops LR3‑IGF‑1‑driven cell proliferation
  • Silencing EGFR with siRNA reduces IGF‑1 receptor protein levels without changing its mRNA
  • Both EGFR inhibition and silencing suppress estradiol‑stimulated cell growth, indicating EGFR’s broader role

Practical Outcomes

  • If you’re using LR3‑IGF‑1, its effectiveness may depend on having normal EGFR signaling. Avoiding strong EGFR inhibitors (like certain cancer drugs) could help maintain LR3‑IGF‑1’s muscle‑building effects. However, the findings are from bovine cells, so direct human recommendations are limited and more research is needed.

Summary

The study shows that a cell‑surface receptor called EGFR is needed for a growth factor called LR3‑IGF‑1 to make muscle‑type cells multiply. When EGFR is blocked or its levels are lowered, LR3‑IGF‑1 can’t boost cell growth, likely because EGFR also helps keep the IGF‑1 receptor protein around. This was seen in cow muscle cells, not humans, and the work was done in a lab setting.

Abstract

The objective of this study was to assess the role of the epidermal growth factor receptor (EGFR) in estradiol-17β (E2)-stimulated proliferation of cultured bovine satellite cells (BSCs). Treatment of BSC cultures with AG1478 (a specific inhibitor of EGFR tyrosine kinase activity) suppresses E2-stimulated BSC proliferation (P < 0.05). In addition, E2-stimulated proliferation is completely suppressed (P < 0.05) in BSCs in which EGFR expression is silenced by treatment with EGFR small interfering RNA (siRNA). These results indicate that EGFR is required for E2 to stimulate proliferation in BSC cultures. Both AG1478 treatment and EGFR silencing also suppress proliferation stimulated by LR3-IGF-1 (an IGF1 analogue that binds normally to the insulin-like growth factor receptor (IGFR)-1 but has little or no affinity for IGF binding proteins) in cultured BSCs (P < 0.05). Even though EGFR siRNA treatment has no effect on IGFR-1β mRNA expression in cultured BSCs, IGFR-1β protein level is substantially reduced in BSCs treated with EGFR siRNA. These data suggest that EGFR silencing results in post-transcriptional modifications that result in decreased IGFR-1β protein levels. Although it is clear that functional EGFR is necessary for E2-stimulated proliferation of BSCs, the role of EGFR is not clear. Transactivation of EGFR may directly stimulate proliferation, or EGFR may function to maintain the level of IGFR-1β which is necessary for E2-stimulated proliferation. It also is possible that the role of EGFR in E2-stimulated BSC proliferation may involve both of these mechanisms.

Study Information

Provider

pubmed

Year

2014

Date

2014-01-19T00:00:00.000Z

DOI

10.1016/j.domaniend.2014.01.001

Citations

8

References

39